Clinical Implication of Cyclooxygenase-2 Expression for Rectal Cancer Patients with Lymph Node Involvement

림프절 전이를 동반한 직장암 환자들에서 Cyclooxygenase-2 발현의 임상적 의미

  • Lee, Hyung-Sik (Departments of Radiation Oncology, Dong-A University School of Medicine) ;
  • Choi, Young-Min (Departments of Radiation Oncology, Dong-A University School of Medicine) ;
  • Hur, Won-Joo (Departments of Radiation Oncology, Dong-A University School of Medicine) ;
  • Kim, Su-Jin (Departments of Pathology, Dong-A University School of Medicine) ;
  • Kim, Dae-Cheol (Departments of Pathology, Dong-A University School of Medicine) ;
  • Roh, Mee-Sook (Departments of Pathology, Dong-A University School of Medicine) ;
  • Hong, Young-Seoub (Departments of Preventive Medicine, Dong-A University School of Medicine) ;
  • Park, Ki-Jae (Departments of Surgery, Dong-A University School of Medicine)
  • 이형식 (동아대학교 의과대학 방사선종양학교실) ;
  • 최영민 (동아대학교 의과대학 방사선종양학교실) ;
  • 허원주 (동아대학교 의과대학 방사선종양학교실) ;
  • 김수진 (동아대학교 의과대학 병리학교실) ;
  • 김대철 (동아대학교 의과대학 병리학교실) ;
  • 노미숙 (동아대학교 의과대학 병리학교실) ;
  • 홍영습 (동아대학교 의과대학 예방의학교실) ;
  • 박기재 (동아대학교 의과대학 외과학교실)
  • Received : 2009.10.12
  • Accepted : 2009.11.26
  • Published : 2009.12.31


Purpose: To assess the influence of cyclooxygenase-2 (COX-2) expression on the survival of patients with a combination of rectal cancer and lymph node metastasis. Materials and Methods: The study included rectal cancer patients treated by radical surgery and postoperative radiotherapy at the Dong-A university hospital from 1998 to 2004. A retrospective analysis was performed on a subset of patients that also had lymph node metastasis. After excluding eight of 86 patients, due to missing tissue samples in three, malignant melanoma in one, treatment of gastric cancer around one year before diagnosis in one, detection of lung cancer after one year of diagnosis in one, liver metastasis in one, and refusal of radiotherapy after 720 cGy in one, 78 patients were analyzed. The immunohistochemistry for COX-2 was conducted with an autostainer (BenchMark; Ventana, Tucson, AZ, USA). An image analyzer (TissueMine; Bioimagene, Cupertino, CA, USA) was used for analysis after scanning (ScanScope; Aperio, Vista, CA, USA). A survival analysis was performed using the Kaplan Meier method and significance was evaluated using the log rank test. Results: COX-2 was stained positively in 62 patients (79.5%) and negatively in 16 (20.5%). A total of 6 (7.7%), 15 (19.2%), and 41 (52.6%) patients were of grades 1, 2, and 3, respectively for COX-2 expression. No correlation was found between being positive of COX-2 patient characteristics, which include age (<60-year old vs. $\geq$60), sex, operation methods (abdominoperineal resection vs. lower anterior resection), degrees of differentiation, tumor size (<5 cm vs. $\geq$5 cm), T stages, N stages, and stages (IIIa, IIIb, IIIc). The 5-year overall and 5-year disease free survival rates for the entire patient population were 57.0% and 51.6%, respectively. The 5-year overall survival rates for the COX-2 positive and negative patients were 53.0% and 72.9%, respectively (p=0.146). Further, the 5-year disease free survival rates for the COX-2 positive and negative patients were 46.3% and 72.7%, respectively (p=0.118). The 5-year overall survival rates were significantly different (p<0.05) for the degree of differentiation, N stage, and stage, whereas the 5-year disease free survival rates were significant for N stage and stage. Conclusion: Being positive for and the degree of COX-2 expression did not have a significant influence on the survival of rectal cancer patients with lymph node metastasis. However, N stage and stage did significantly influence the rateof survival. Further analysis of a greater sample size is necessary for the verification of the effect of COX-2 expression on the survival of rectal cancer patients with lymph node involvement.

목 적: 림프절 전이가 동반된 직장암 환자들에서 cyclooxygenase-2 (COX-2) 발현이 생존율에 미치는 영향을 조사 하고자 한다. 대상 및 방법: 1998년부터 2004년까지 직장암으로 동아대병원에서 근치적 수술과 수술 후 방사선치료를 받은 환자들 중에서 림프절 전이가 동반된 경우를 대상으로 후향적분석을 하였다. 86명 중에서 수술 후 조직을 찾을 수 없는 3명, 악성 흑색종 1명, 진단 전후 2년 내에 위암과 폐암이 발생한 각 1명, 진단 시에 간 전이가 있었던 1명, 720 cGy 후 방사선치료를 거부한 1명 등을 제외한 78명을 대상으로 분석하였다. COX-2에 대한 면역조직화학염색은 자동면역염색기로 하였고, 스캔한 후, 영상분석기를 이용하여 분석하였다. Kaplan-Meier 생존율 분석을 하였고, Log rank 검사로 유의성을 조사하였다. 결 과: 면역조직화학염색에서 COX-2 양성이 62명(79.5%), 음성이 16명(20.5%)이었고, 양성도가 1, 2, 3인 환자들이 각각 6명(7.7%), 15명(19.2%), 41명(52.6%)이었다. 환자의 나이(60세 미만, 이상), 성별, 수술 방법(복회음절제술, 하위전방절제술), 세포의 분화도, 종양의 크기(5 cm 미만, 5 cm 이상), T병기, N병기, 병기(IIIa, IIIb, IIIc), 등에 따른 COX-2 발현의 차이는 없었다. 전체 환자의 5년 생존율과 무병생존율은 각각 57.0%, 51.6%였다. COX-2 음성과 양성인 환자들의 5년 생존율이 72.9%와 53.0% (p=0.146), 5년 무병생존율이 72.7%와 46.3% (p=0.118)였다. COX-2 양성도가 0, 1, 2, 3인 환자들의 5년 생존율은 각각 72.9, 50.0 51.3, 53.1%였고(p=0.495), 5년 무병생존율은 각각 72.7, 50.0, 46.7, 45.1%였다(p=0.451). 5년 생존율은 악성종양 세포의 분화도, N병기, 병기, 등에 따라서, 5년 무병생존율은 N병기, 병기, 등에 따라서 유의한 차이가 있었다(p<0.05). 결 론: 림프절 전이가 동반된 직장암 환자에서 COX-2의 발현 여부와 정도는 생존율에 유의한 영향을 주지는 않았다. 하지만 향후 보다 많은 환자군을 대상으로 연구하여, COX-2 발현이 직장암의 예후에 미치는 영향을 규명해야 할 것으로 생각된다.



Supported by : 동아대학교


  1. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-1596
  2. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-246
  3. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-614
  4. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993;72:1171-1177<1171::AID-CNCR2820720407>3.0.CO;2-D
  5. Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users: the Polyp Prevention Study Group. J Natl Cancer Inst 1993;85:912-916
  6. Logan RF, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993;307:285-289
  7. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 1996;5:955-960
  8. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899
  9. Joo YE, Kim HS, Min SW, et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer 2002;31:147-154
  10. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254-1257
  11. Chinery R, Coffey RJ, Graves-Deal R, et al. Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res 1999;59:2739-2746
  12. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal antiinflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997;3:1679-1683
  13. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716
  14. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-3340
  15. Cafiero F, Gipponi M, Lionetto R. Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report. J Surg Oncol 2003;83:140-146
  16. Lee JH, Lee JH, Ahn JH, et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J Clin Oncol 2002;20:1751-1758
  17. Chang SK, Kim JW, Oh D, Chong SY, Shin HS. Postoperative adjuvant chemoradiotherapy in rectal cancer. J Korean Soc Ther Radiol Oncol 2006;24:157-163
  18. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002;97:1037-1041
  19. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10:8465-8471
  20. Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-328
  21. Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 2002;19:527-534
  22. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064-4068
  23. Petersen S, Haroske G, Hellmich G, Ludwig K, Petersen C, Eicheler W. COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res 2002;22:1225-1230
  24. Soumaoro LT, Uetake H, Takagi Y, et al. Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum 2006;49:392-398
  25. Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P. Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 2005;11:4754-4760